Format
Sort by
Items per page

Send to

Choose Destination

Best matches for oncolytic sindbis virus:

Oncolytic Alphaviruses in Cancer Immunotherapy. Lundstrom K et al. Vaccines (Basel). (2017)

Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability. Kueberuwa G et al. Hum Gene Ther Methods. (2014)

Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain. Takenouchi A et al. Pediatr Surg Int. (2015)

Search results

Items: 1 to 20 of 24

1.

Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity.

Scherwitzl I, Hurtado A, Pierce CM, Vogt S, Pampeno C, Meruelo D.

Mol Ther Oncolytics. 2018 May 3;9:51-63. doi: 10.1016/j.omto.2018.04.004. eCollection 2018 Jun 29.

2.

Oncolytic Alphaviruses in Cancer Immunotherapy.

Lundstrom K.

Vaccines (Basel). 2017 Apr 12;5(2). pii: E9. doi: 10.3390/vaccines5020009. Review.

3.

Oncolytic viral therapy for neuroblastoma cells with Sindbis virus AR339 strain.

Takenouchi A, Saito K, Saito E, Saito T, Hishiki T, Matsunaga T, Isegawa N, Yoshida H, Ohnuma N, Shirasawa H.

Pediatr Surg Int. 2015 Dec;31(12):1151-9. doi: 10.1007/s00383-015-3784-y. Epub 2015 Aug 23.

PMID:
26298056
4.

Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability.

Kueberuwa G, Cawood R, Tedcastle A, Seymour LW.

Hum Gene Ther Methods. 2014 Apr;25(2):154-65. doi: 10.1089/hgtb.2013.202.

PMID:
24568203
5.

Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells.

Paglino JC, Andres W, van den Pol AN.

J Virol. 2014 May;88(9):4932-42. doi: 10.1128/JVI.03508-13. Epub 2014 Feb 19.

6.

Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.

Granot T, Yamanashi Y, Meruelo D.

Mol Ther. 2014 Jan;22(1):112-22. doi: 10.1038/mt.2013.215. Epub 2013 Sep 12.

7.

Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting.

Ylösmäki E, Martikainen M, Hinkkanen A, Saksela K.

J Virol. 2013 Jan;87(1):335-44. doi: 10.1128/JVI.01940-12. Epub 2012 Oct 17.

8.

Sindbis viral vectors target hematopoietic malignant cells.

Suzme R, Tseng JC, Levin B, Ibrahim S, Meruelo D, Pellicer A.

Cancer Gene Ther. 2012 Nov;19(11):757-66. doi: 10.1038/cgt.2012.56. Epub 2012 Sep 7.

PMID:
22956041
9.

The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.

Granot T, Meruelo D.

Cancer Gene Ther. 2012 Aug;19(8):588-91. doi: 10.1038/cgt.2012.33. Epub 2012 Jun 8.

PMID:
22677940
10.

Imaging early steps of sindbis virus infection by total internal reflection fluorescence microscopy.

Gu Y, Yang Y, Liu Y.

Adv Virol. 2011;2011:535206. doi: 10.1155/2011/535206. Epub 2011 Nov 24.

11.

Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.

Huang PY, Guo JH, Hwang LH.

Mol Ther. 2012 Feb;20(2):298-305. doi: 10.1038/mt.2011.245. Epub 2011 Nov 8.

12.

Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.

Paglino JC, van den Pol AN.

J Virol. 2011 Sep;85(18):9346-58. doi: 10.1128/JVI.00723-11. Epub 2011 Jul 6.

13.

Activation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectors.

Granot T, Venticinque L, Tseng JC, Meruelo D.

PLoS One. 2011;6(6):e20598. doi: 10.1371/journal.pone.0020598. Epub 2011 Jun 2.

14.

Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells.

Mohankumar V, Dhanushkodi NR, Raju R.

Biochem Biophys Res Commun. 2011 Mar 11;406(2):262-7. doi: 10.1016/j.bbrc.2011.02.030. Epub 2011 Feb 18.

15.

Alphavirus vectors for cancer therapy.

Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C.

Virus Res. 2010 Nov;153(2):179-96. doi: 10.1016/j.virusres.2010.07.027. Epub 2010 Aug 6. Review.

PMID:
20692305
16.

Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.

Saito K, Shirasawa H, Isegawa N, Shiiba M, Uzawa K, Tanzawa H.

Oral Oncol. 2009 Dec;45(12):1021-7. doi: 10.1016/j.oraloncology.2009.09.002. Epub 2009 Oct 14. Review.

PMID:
19833547
17.

Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor.

Tseng JC, Granot T, DiGiacomo V, Levin B, Meruelo D.

Cancer Gene Ther. 2010 Apr;17(4):244-55. doi: 10.1038/cgt.2009.70. Epub 2009 Oct 2.

18.

Oncolytic activity of Sindbis virus in human oral squamous carcinoma cells.

Saito K, Uzawa K, Kasamatsu A, Shinozuka K, Sakuma K, Yamatoji M, Shiiba M, Shino Y, Shirasawa H, Tanzawa H.

Br J Cancer. 2009 Aug 18;101(4):684-90. doi: 10.1038/sj.bjc.6605209. Epub 2009 Jul 28.

19.

Oncolytic vaccinia virus: from bedside to benchtop and back.

Thorne SH.

Curr Opin Mol Ther. 2008 Aug;10(4):387-92.

PMID:
18683104
20.

Supplemental Content

Loading ...
Support Center